In a presentation titled Readmission for Stroke and Quality of Care Among Hospitalized Patients With Transient Ischemic Attack: Real World Delivery of Care, Emily C. O'Brian, PhD, from Duke University School of Medicine, presented results from the American Heart Association's Get With the Guidelines (GWTG)-Stroke program. GWTG is a hospital improvement program designed to improve adherence to evidence-based care.
Among patients who have had transient ischemic attacks (TIAs), those who are in the highest risk category were least likely to receive optimal care to prevent future hospitalizations for TIA or stroke.
In a presentation; “Readmission for Stroke and Quality of Care Among Hospitalized Patients With Transient Ischemic Attack: Real World Delivery of Care,” Emily C. O’Brian, PhD, instructor, Duke University School of Medicine, presented results from the American Heart Association’s Get With the Guidelines (GWTG)-Stroke program.
Researchers used data for 58,809 TIA patients aged over 65 years enrolled in the GWTG-Stroke Registry (2003-2008). They estimated the risk for 1-year hospital admission for stroke or subsequent TIA using demographics and past medical history. The cohort was then divided into 5 groups based on their degree of risk. Researchers then assessed the quality of care based on 5 metrics reflecting whether eligible patients received: early antithrombotics, discharge antithrombotics, anticoagulants for patients with atrial fibrillation, anticoagulation therapy, statins for low-density lipoprotein cholesterol (LDL-C) levels greater than 100 mg/dL, and smoking cessation counseling. Researchers then calculated a defect-free care (DFC) measure to reflect the overall quality of care.
The study found the risk of readmission was 11.8% overall. Disparities between the lowest and highest risk categories were found for receipt of statins, anticoagulation therapy, smoking cessation counseling, and DFC. The quality-of-care metric for those with elevated LDL-C was least optimal. For the healthiest group of patients, approximately two-thirds received a statin. By comparison, approximately 56% received a statin.
The GWTG program is AHA’s hospital improvement program designed to improve adherence to evidence-based care. The program provides hospitals with a Web-based patient management tool, decision support, and real-time benchmarking capabilities. The GWTG-Stroke Fact Sheet can be found on the AHA website (https://www.heart.org/idc/groups/heart-public/@wcm/@private/@hcm/@gwtg/documents/downloadable/ucm_310976.pdf).
Dr O’Brian noted that protocols for optimal treatment are already in place to help remind healthcare providers of the appropriate care for a particular patient. “We already have a tool that reminds hospitals to follow recommendations ranging from hospital admission to helping the patient out the door,” Dr O’Brian said in an interview. However, more steps can be taken to ensure that the patients who are at highest risk are given the appropriate treatments. “Standard risk assessment delivery of optimal TIA patient care is needed.”
GLP-1 Receptor Agonists Reduce Adverse Cardiovascular Outcomes, Improve Survival
August 2nd 2025Studies found that glucagon-like peptide-1 (GLP-1) receptor agonists were valuable tools in improving outcomes and survival in those with coronary plaque and after ST-elevation myocardial infarction.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
AI, GLP-1s Among Topics to Be Discussed During ASPC Annual Meeting
July 28th 2025The American Society for Preventive Cardiology (ASPC) Congress on Cardiovascular Disease Prevention features multiple sessions on different methods of treating and preventing cardiovascular disease, including through the use of artificial intelligence (AI) and glucagon-like peptide-1 (GLP-1) receptor agonists.
Read More